國藥一致(000028.SZ):董事會通過關於與兩廣區域內多家醫院開展創新項目的議案
格隆匯 12 月 29日丨國藥一致(000028.SZ)公佈,公司第八屆董事會第二十一次會議決議,審議通過了《關於與兩廣區域內多家醫院開展創新項目的議案》;
為應對市場變化和同行競爭,搶抓廣東、廣西兩省醫療改革中出現的醫療合作機遇,穩固公司在兩廣區域內醫院的藥品配送份額,提高與醫院合作粘度,董事會同意公司下屬國藥控股廣州有限公司、國藥控股廣西有限公司聯合區域子公司運用自有及自籌資金,根據兩廣區域內12家醫院的實際情況和需求,運用現代化供應鏈管理理念和先進的供應鏈管理模式,與相關醫院展開創新項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.